Medicine and Dentistry
Radiation Therapy
100%
Breast Cancer
87%
Neoplasm
74%
Malignant Neoplasm
62%
Chemotherapy
53%
Overall Survival
50%
Head and Neck Cancer
35%
Disease
35%
Cohort Analysis
29%
Melanoma
28%
Recurrent Disease
27%
Quality of Life
27%
Non Small Cell Lung Cancer
26%
Metastatic Colorectal Cancer
23%
Metastatic Carcinoma
22%
Positron Emission Tomography-Computed Tomography
20%
Magnetic Resonance Imaging
20%
Oncology
16%
Hazard Ratio
16%
Progression Free Survival
16%
Clinical Trial
16%
Prognostic Factor
16%
Pancreas Cancer
15%
Biological Marker
15%
Adverse Event
14%
Immunotherapy
14%
Neck
13%
Lung
13%
Comorbidity
13%
Surgery
13%
Colorectal Carcinoma
13%
Cancer Therapy
13%
Primary Tumor
12%
Diagnosis
12%
Squamous Cell Carcinoma
12%
Ganglioglioma
12%
Randomized Controlled Trial
12%
Head and Neck Squamous Cell Carcinoma
12%
Glioblastoma
11%
Lung Cancer
11%
Treatment Planning
11%
Arm
11%
Symptomatic Treatment
11%
Systematic Review
11%
Chemoradiotherapy
11%
Stereotactic Body Radiation Therapy
11%
Estrogen Receptor
10%
Cancer Cell
10%
Metastatic Melanoma
10%
Prostate Cancer
10%
Systemic Therapy
10%
Oxaliplatin
10%
Patient-Reported Outcome
10%
Testis Cancer
9%
Biopsy Technique
9%
Computer Assisted Tomography
9%
Metastatic Breast Cancer
9%
Tamoxifen
8%
Intensity Modulated Radiation Therapy
8%
Meta-Analysis
8%
Rectum Cancer
8%
Prevalence
8%
Placebo
8%
Epidermal Growth Factor Receptor
8%
Peritoneum Metastasis
8%
Adjuvant Therapy
8%
Ovarian Cancer
8%
Radiation Oncology
8%
Survival Rate
8%
Adjuvant Chemotherapy
7%
Proportional Hazards Model
7%
Volumetric Modulated Arc Therapy
7%
Cancer Treatment
7%
Geriatric Assessment
7%
Lymph Node
7%
Odds Ratio
7%
Tumor Cell
7%
Distant Metastasis
7%
Cancer
7%
Clinician
7%
Immune Checkpoint Inhibitor
7%
P16
7%
Fluorodeoxyglucose F 18
6%
Fluorouracil
6%
Hormone Therapy
6%
Targeted Therapy
6%
Volume CT
6%
Contouring
6%
Randomized Clinical Trial
6%
Combination Therapy
6%
Adaptive Radiotherapy
6%
Health Care
6%
Frailty
6%
Monotherapy
6%
Cancer Radiotherapy
6%
Capecitabine
6%
Cisplatin
6%
Side Effect
6%
Lymph Node Metastasis
6%
Drug Megadose
6%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
68%
Overall Survival
57%
Chemotherapy
56%
Neoplasm
56%
Malignant Neoplasm
53%
Metastatic Colorectal Cancer
42%
Melanoma
27%
Progression Free Survival
26%
Disease
26%
Non Small Cell Lung Cancer
25%
Oxaliplatin
20%
Head and Neck Cancer
20%
Cohort Study
19%
Adverse Event
18%
Placebo
17%
Biological Marker
17%
Recurrent Disease
17%
Clinical Trial
15%
Comorbidity
15%
Cetuximab
15%
Lung Cancer
15%
Irinotecan
14%
Metastatic Melanoma
13%
Immunotherapy
13%
Metastatic Breast Cancer
13%
Fluorouracil
12%
Bevacizumab
12%
Colorectal Carcinoma
12%
Chemoradiation Therapy
12%
Cisplatin
11%
Pancreas Cancer
11%
Epidermal Growth Factor Receptor
10%
Ovary Cancer
10%
Docetaxel
10%
Estrogen Receptor
10%
Capecitabine
9%
Phase II Trials
9%
Polyethylene Terephthalate
9%
Monotherapy
9%
Nausea and Vomiting
9%
Prevalence
8%
Paclitaxel
8%
Squamous Cell Carcinoma
8%
Ipilimumab
8%
Antiemetic Agent
8%
Glioblastoma
8%
Primary Tumor
8%
Randomized Controlled Trial
7%
Prostate Cancer
7%
Survival Rate
7%
Tamoxifen
7%
Epirubicin
7%
Cyclophosphamide
7%
Combination Therapy
7%
Nausea
7%
Side Effect
6%
Head and Neck Squamous Cell Carcinoma
6%
Gemcitabine
6%
Immune Checkpoint Inhibitor
6%
Peritoneum Metastasis
6%
Nivolumab
6%
Metastasis
6%
Tolerability
5%
Chemotherapy Induced Nausea and Vomiting
5%
Solid Malignant Neoplasm
5%
Estrogen Receptor Positive Breast Cancer
5%
Carboplatin
5%
Brain Metastasis
5%
Recurrence Free Survival
5%